ATAI AtaiBeckley Inc.
Price Chart
Executive Summary
AtaiBeckley announced positive Phase 2a results for BPL-003 in treatment-resistant depression, showing a 66.7% antidepressant response rate by Day 2 and durable responses through Week 12, with no serious adverse events. The drug has FDA Breakthrough Therapy Designation, and Phase 3 initiation is on track for Q2 2026.
Actionable Insight
This data strengthens BPL-003's profile ahead of Phase 3, supporting potential approval pathway. Traders should monitor for upcoming Part 4 data in Q4 2026 and formal Phase 3 trial launch in Q2 2026 as next catalysts. Despite recent insider selling, the clinical progress may attract institutional interest.
Key Facts
- BPL-003 achieved 66.7% antidepressant response rate (≥50% MADRS reduction) by Day 2 in both 10 mg and 12 mg cohorts (n=12 total)
- Durable response at Week 12: 83% in 10 mg cohort, 66.7% in 12 mg cohort
- No serious adverse events reported; mean discharge time ~100 minutes post-dose
- FDA Breakthrough Therapy Designation granted October 2025
- Phase 3 initiation on track for Q2 2026 following End-of-Phase 2 meeting with FDA
Financial Impact
Non-dilutive clinical catalyst with high optionality value; de-risks Phase 3 initiation
Risk Factors
- Small trial size (n=12) limits statistical power
- Open-label design introduces bias risk
- Phase 3 may not replicate efficacy
- Regulatory hurdles remain despite Breakthrough designation
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269923 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
6d ago
|
8-K
| $4.53 $4.50 | ▼ −0.66% | ▼ −1.06% | $3.89 (−14.13%) |
|
May 12, 2026
28d ago
|
Press Release
| $4.15 $4.24 | ▲ +2.17% | ▲ +1.59% | $3.89 (−6.27%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.34 $4.33 | ▼ −0.23% | ▲ +0.25% | $3.89 (−10.37%) |
|
Apr 20, 2026
7w ago
|
144
| $4.87 $4.71 | ▼ −3.29% | ▼ −4.30% | $3.89 (−20.12%) |
|
Apr 8, 2026
8w ago
|
Press Release
| $3.76 $3.70 | ▼ −1.60% | ▼ −2.17% | $3.89 (+3.46%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $3.38 $3.54 | ▲ +4.73% | ▲ +4.17% | $3.89 (+15.09%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $3.65 $3.56 | ▼ −2.47% | ▼ −1.07% | $3.89 (+6.58%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $4.14 $4.06 | ▼ −1.93% | ▼ −1.83% | $3.89 (−6.04%) |
|
Mar 6, 2026
13w ago
|
Press Release
| $3.39 $3.89 | ▲ +14.75% | ▲ +13.90% | $3.89 (+14.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access